New and emerging drugs for the treatment of advanced cutaneous squamous cell carcinoma
This article reviews the current systemic therapy options for CSCC with a focus on ICI and emerging promising therapies in the treatment of this challenging disease.EXPERT OPINION: ICI is currently the most effective and tolerable systemic therapy in the treatment of non-immunosuppressed advanced CSCC and can lead to cure in a subset of patients. Combinatorial therapies to overcome resistance to ICI may further increase the proportion of patients who will benefit from ICI and may help improve the quantity and quality of life of patients affected by this disease.PMID:37144289 | DOI:10.1080/14728214.2023.2208345 (Source: Exp...
Source: Expert Opinion on Emerging Drugs - May 5, 2023 Category: Drugs & Pharmacology Authors: Renata Ferrarotto Flavia Bonini Luana Guimaraes De Sousa Source Type: research
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?
Expert Opin Emerg Drugs. 2023 May 9:1-7. doi: 10.1080/14728214.2023.2211346. Online ahead of print.ABSTRACTINTRODUCTION: Lung cancer is the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) as the most common subtype. In the past decades, immunotherapy deeply changed paradigms for care of newly diagnosed advanced NSCLC patients without oncogenic driver mutations. An immunotherapy-based regimen alone or in combination to chemotherapy was crowned as the preferred option to choice, according to worldwide guideline.AREAS COVERED: Newly diagnoses of advanced NCSLC occurred predominantly in...
Source: Expert Opinion on Emerging Drugs - May 5, 2023 Category: Drugs & Pharmacology Authors: Francesca Casaluce Cesare Gridelli Source Type: research
New and emerging drugs for the treatment of advanced cutaneous squamous cell carcinoma
This article reviews the current systemic therapy options for CSCC with a focus on ICI and emerging promising therapies in the treatment of this challenging disease.EXPERT OPINION: ICI is currently the most effective and tolerable systemic therapy in the treatment of non-immunosuppressed advanced CSCC and can lead to cure in a subset of patients. Combinatorial therapies to overcome resistance to ICI may further increase the proportion of patients who will benefit from ICI and may help improve the quantity and quality of life of patients affected by this disease.PMID:37144289 | DOI:10.1080/14728214.2023.2208345 (Source: Exp...
Source: Expert Opinion on Emerging Drugs - May 5, 2023 Category: Drugs & Pharmacology Authors: Renata Ferrarotto Flavia Bonini Luana Guimaraes De Sousa Source Type: research
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?
Expert Opin Emerg Drugs. 2023 May 9:1-7. doi: 10.1080/14728214.2023.2211346. Online ahead of print.ABSTRACTINTRODUCTION: Lung cancer is the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) as the most common subtype. In the past decades, immunotherapy deeply changed paradigms for care of newly diagnosed advanced NSCLC patients without oncogenic driver mutations. An immunotherapy-based regimen alone or in combination to chemotherapy was crowned as the preferred option to choice, according to worldwide guideline.AREAS COVERED: Newly diagnoses of advanced NCSLC occurred predominantly in...
Source: Expert Opinion on Emerging Drugs - May 5, 2023 Category: Drugs & Pharmacology Authors: Francesca Casaluce Cesare Gridelli Source Type: research
New and emerging drugs for the treatment of advanced cutaneous squamous cell carcinoma
This article reviews the current systemic therapy options for CSCC with a focus on ICI and emerging promising therapies in the treatment of this challenging disease.EXPERT OPINION: ICI is currently the most effective and tolerable systemic therapy in the treatment of non-immunosuppressed advanced CSCC and can lead to cure in a subset of patients. Combinatorial therapies to overcome resistance to ICI may further increase the proportion of patients who will benefit from ICI and may help improve the quantity and quality of life of patients affected by this disease.PMID:37144289 | DOI:10.1080/14728214.2023.2208345 (Source: Exp...
Source: Expert Opinion on Emerging Drugs - May 5, 2023 Category: Drugs & Pharmacology Authors: Renata Ferrarotto Flavia Bonini Luana Guimaraes De Sousa Source Type: research
